300122 智飞生物
2025/09 - 九个月
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额2,985,019(4,413,989)8,996,3701,989,0338,507,592
投资活动产生之现金流量净额(439,565)(925,583)(976,599)(1,497,955)(2,019,337)
筹资活动产生之现金流量净额(2,754,297)1,697,887(4,293,867)(2,172,647)(3,589,911)
汇率变动对现金及现金等价物的影响(408)1,252(2,303)17,557(9,661)
现金及现金等价物净增加/(减少)(209,251)(3,640,434)3,723,601(1,664,012)2,888,682
期初现金及现金等价物余额2,704,0696,339,2902,615,6894,279,7011,391,018
期末现金及现金等价物余额2,494,8192,698,8566,339,2902,615,6894,279,701